Skip to main content
Top
Published in: Journal of Ovarian Research 1/2015

Open Access 01-12-2015 | Research

Relationship of tumor marker CA125 and ovarian tumor stem cells: preliminary identification

Authors: Hui Zhang, Yongan Yang, Yifeng Wang, Xinping Gao, Weiming Wang, Hui Liu, Haipeng He, Yijuan Liang, Kun Pan, Hongli Wu, Junrong Shi, Huiling Xue, Ling Liang, Zhihuci Cai, Yanfang Fan, Yanyan Zhang

Published in: Journal of Ovarian Research | Issue 1/2015

Login to get access

Abstract

Purpose

The purpose of this study is to identify a prospective association between CA125 and tumorigenic ovarian cancer cells, using the new method of orthotopic transplantation (1).

Method

After making the surgical ovarian cancer specimen into cell suspension, we separated the tumorigenic cells from the nontumorigenic cancer cells based on cell surface marker (cancer antigen CA125 and lineage markers) expression. We developed a SCID mice model in which the CA125+/ lineage- and CA125-/ lineage- cells were injected into ovarian parenchyma by use of a microinjector. As a measure of effectiveness of tumor-forming, tumor weight, abdominal distension, ascites volume and activity, subcutaneous fat were determined or observed. Immunohistochemistry was done to determine tumor cell markers.

Results

We found that the cells of CA125+/ lineage- were able to form new tumors; whereas, an equal quantity of CA125-/lineage- cells failed to form any tumors. The new generated tumor contained additional CA125-/lineage- tumorigenic cells as well as the phenotypically diverse population of nontumorigenic cells. Quantities were judged to be significantly different P < 0.0001.

Conclusion

CA125+/ lineage- cells, which may be ovarian cancer stem cells, were the source for tumor recurrence. The strategies designed to target this cell population may lead to more effective therapies.
Literature
1.
go back to reference Borley JWC, Brown RGS. Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? Syst Lit Rev. 2012;7(107):1069–74. Borley JWC, Brown RGS. Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? Syst Lit Rev. 2012;7(107):1069–74.
2.
3.
go back to reference Hui Zhang XG, Yongan Y. New construction of an animal model for the orthotopic transplantation of an ovarian tumor. J Osvarian Res. 2014;7:64.CrossRef Hui Zhang XG, Yongan Y. New construction of an animal model for the orthotopic transplantation of an ovarian tumor. J Osvarian Res. 2014;7:64.CrossRef
4.
go back to reference Bon GG, Kenemans P, Verstraeten R. Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values. Am J Obstet Gynecol. 1996;174(1 Pt1):107–14.CrossRefPubMed Bon GG, Kenemans P, Verstraeten R. Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values. Am J Obstet Gynecol. 1996;174(1 Pt1):107–14.CrossRefPubMed
5.
go back to reference Peters III WA. CA-125. Use as a tumor marker with mixed mesodermal tumors of the female genital tract. Cancer. 1986;58(12):2625–7.CrossRefPubMed Peters III WA. CA-125. Use as a tumor marker with mixed mesodermal tumors of the female genital tract. Cancer. 1986;58(12):2625–7.CrossRefPubMed
6.
go back to reference Seidel SBV. A hypoxicnicle regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain. 2010;133(4):983–95.CrossRefPubMed Seidel SBV. A hypoxicnicle regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain. 2010;133(4):983–95.CrossRefPubMed
7.
go back to reference Hirohashi YTT, Inoda S. Immune response against tumor antigens expressed on human cancer stem-like cells/tumor-initiating cells. Immunother. 2010;2(2):201–11.CrossRef Hirohashi YTT, Inoda S. Immune response against tumor antigens expressed on human cancer stem-like cells/tumor-initiating cells. Immunother. 2010;2(2):201–11.CrossRef
8.
go back to reference Ahmed NAK, Findlay J. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance. J Cell Biochem. 2013;114(1):21–34.CrossRefPubMed Ahmed NAK, Findlay J. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance. J Cell Biochem. 2013;114(1):21–34.CrossRefPubMed
9.
go back to reference Levanon KNV, Piao HY. Primary ex-vivo cul-tures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene. 2010;29(8):1103–13.CrossRefPubMedCentralPubMed Levanon KNV, Piao HY. Primary ex-vivo cul-tures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene. 2010;29(8):1103–13.CrossRefPubMedCentralPubMed
10.
11.
go back to reference Grasse·Gehling PCC. CD133 as a biomarker for putative cancer stem cells in solid tumours:limitations, problems and challenges. J Pathol. 2013;229(3):355–78.CrossRef Grasse·Gehling PCC. CD133 as a biomarker for putative cancer stem cells in solid tumours:limitations, problems and challenges. J Pathol. 2013;229(3):355–78.CrossRef
12.
go back to reference Muraro MVS. CD133+, CD166 + CD44+, and CD24+ CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human colorectal cancer cell line. Stem Cells Transl Med. 2012;1(8):592–603.CrossRefPubMedCentralPubMed Muraro MVS. CD133+, CD166 + CD44+, and CD24+ CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human colorectal cancer cell line. Stem Cells Transl Med. 2012;1(8):592–603.CrossRefPubMedCentralPubMed
13.
go back to reference Lee YW. Nestin expresstion as an indicator of cervical cancer initiatior. Eur J Gynaecol Oncol Oncol. 2013;34(3):238–42. Lee YW. Nestin expresstion as an indicator of cervical cancer initiatior. Eur J Gynaecol Oncol Oncol. 2013;34(3):238–42.
15.
go back to reference Wasaki HS. Cancer stem cells and their niche. Cancer Sci. 2009;7:1166-72-6. Wasaki HS. Cancer stem cells and their niche. Cancer Sci. 2009;7:1166-72-6.
16.
go back to reference Gupta PBOTT, Jiang G. Idenification of selective inhibitons of cancer stem cell by high -throughput screening. Cell. 2009;138:546–659.CrossRef Gupta PBOTT, Jiang G. Idenification of selective inhibitons of cancer stem cell by high -throughput screening. Cell. 2009;138:546–659.CrossRef
17.
go back to reference Ishikawa M, Yaginuma Y, Hayashi H, Shimizu T, Endo Y, Taniguchi N. Reactivity of a monoclonal antibody to manganese superoxide dismutase with human ovarian carcinoma. Cancer Res. 1990;50(8):2538–42.PubMed Ishikawa M, Yaginuma Y, Hayashi H, Shimizu T, Endo Y, Taniguchi N. Reactivity of a monoclonal antibody to manganese superoxide dismutase with human ovarian carcinoma. Cancer Res. 1990;50(8):2538–42.PubMed
18.
go back to reference Bast Jr RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68(5):1331–7.CrossRefPubMedCentralPubMed Bast Jr RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68(5):1331–7.CrossRefPubMedCentralPubMed
19.
go back to reference Schummer M, Drescher C, Forrest R, Gough S, Thorpe J, Hellstrom I, et al. Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. Gynecol Oncol. 2012;125(1):65–9.CrossRefPubMedCentralPubMed Schummer M, Drescher C, Forrest R, Gough S, Thorpe J, Hellstrom I, et al. Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. Gynecol Oncol. 2012;125(1):65–9.CrossRefPubMedCentralPubMed
20.
go back to reference Granato T, Midulla C, Longo F, Colaprisca B, Frati L, Anastasi E. Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer. Tumour Biol. 2012;33(5):1335–9.CrossRefPubMed Granato T, Midulla C, Longo F, Colaprisca B, Frati L, Anastasi E. Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer. Tumour Biol. 2012;33(5):1335–9.CrossRefPubMed
21.
go back to reference Cipriano SC, Chen L, Kumar TR, Matzuk MM. Follistatin is a modulator of gonadal tumor progression and the activin-induced wasting syndrome in inhibin-deficient mice. Endocrinology. 2000;141(7):2319–27.PubMed Cipriano SC, Chen L, Kumar TR, Matzuk MM. Follistatin is a modulator of gonadal tumor progression and the activin-induced wasting syndrome in inhibin-deficient mice. Endocrinology. 2000;141(7):2319–27.PubMed
Metadata
Title
Relationship of tumor marker CA125 and ovarian tumor stem cells: preliminary identification
Authors
Hui Zhang
Yongan Yang
Yifeng Wang
Xinping Gao
Weiming Wang
Hui Liu
Haipeng He
Yijuan Liang
Kun Pan
Hongli Wu
Junrong Shi
Huiling Xue
Ling Liang
Zhihuci Cai
Yanfang Fan
Yanyan Zhang
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Journal of Ovarian Research / Issue 1/2015
Electronic ISSN: 1757-2215
DOI
https://doi.org/10.1186/s13048-015-0132-8

Other articles of this Issue 1/2015

Journal of Ovarian Research 1/2015 Go to the issue